iNCDSS based insulin regime
PreclinicalSmall molecule
iNCDSS based insulin regime is one of 82 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
GZR4
GGan and Lee Pharmaceuticals, USA
Phase 3
Ganagliflozin
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
HM11260C
Hanmi Pharmaceutical Company LimitedPhase 3
Dorzagliatin
HHua Medicine Limited
Phase 3
TG103
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iNCDSS based insulin regime. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Zhongshan Hospital